SUMOylation alterations are associated with multidrug resistance in hepatocellular carcinoma

Qin,Yu; Bao,Huijing; Pan,Yi; Yin,Meilin; Liu,Yunde; Wu,Shangwei; Li,Huikai

doi:10.3892/mmr.2014.1882

SUMOylation alterations are associated with multidrug resistance in hepatocellular carcinoma

Authors:
- Yu Qin
- Huijing Bao
- Yi Pan
- Meilin Yin
- Yunde Liu
- Shangwei Wu
- Huikai Li
View Affiliations

Affiliations: Department of Diagnostics, College of Basic Medical Science, Tianjin Medical University, Tianjin 300070, P.R. China, School of Laboratory Medicine, Tianjin Medical University, Tianjin 300203, P.R. China, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China, Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China
Published online on: January 2, 2014 https://doi.org/10.3892/mmr.2014.1882
Pages: 877-881

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The development of multidrug resistance (MDR) in hepatocellular carcinoma (HCC) may markedly reduce the efficacy of its chemotherapeutic treatment. However, the mechanism regulating the development of MDR in these tumors remains unknown. Given the emerging role of small ubiquitin‑like modifier (SUMO)ylation in tumorigenesis, the possibility that it may also be involved in MDR development was investigated. The expression of SUMO‑1 was first analyzed using immunohistochemistry in 20 cases of HCC. Nuclear SUMO‑1 immunostaining was observed to be significantly increased in HCC specimens compared with matched adjacent non‑neoplastic controls. To further investigate the potential role of SUMOylation in MDR in HCC, a multidrug‑resistant HCC cell line, HepG2/R, was established by exposing HCC cells to gradually increasing concentrations of 5‑fluorouracil. Western blot analysis revealed that the total levels of SUMO‑1‑conjugated proteins were markedly increased in HepG2/R cells compared with parental HepG2 cells. Furthermore, the expression of ubiquitin‑like modifier activating enzyme 2 and sentrin‑specific protease 1, important enzymes in the SUMOylation cascade, were markedly upregulated in the HepG2/R cell line. These findings support the hypothesis that SUMOylation is important in the development of MDR in HCC.

View Figures

View References

1	Geiss-Friedlander R and Melchior F: Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 8:947–956. 2007. View Article : Google Scholar : PubMed/NCBI
2	Meluh PB and Koshland D: Evidence that the MIF2 gene of Saccharomyces cerevisiae encodes a centromere protein with homology to the mammalian centromere protein CENP-C. Mol Biol Cell. 6:793–807. 1995.PubMed/NCBI
3	Shen Z, Pardington-Purtymun PE, Comeaux JC, Moyzis RK and Chen DJ: UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins. Genomics. 36:271–279. 1996. View Article : Google Scholar : PubMed/NCBI
4	Okura T, Gong L, Kamitani T, Wada T, Okura I, Wei CF, Chang HM and Yeh ET: Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J Immunol. 157:4277–4281. 1996.PubMed/NCBI
5	Seeler JS and Dejean A: Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol. 4:690–699. 2003. View Article : Google Scholar : PubMed/NCBI
6	Wadosky KM and Willis MS: The story so far: post-translational regulation of peroxisome proliferator-activated receptors by ubiquitination and SUMOylation. Am J Physiol Heart Circ Physiol. 302:H515–H526. 2012. View Article : Google Scholar : PubMed/NCBI
7	Gong L, Li B, Millas S and Yeh ET: Molecular cloning and characterization of human AOS1 and UBA2, components of the sentrin-activating enzyme complex. FEBS Lett. 448:185–189. 1999. View Article : Google Scholar : PubMed/NCBI
8	Muller S, Berger M, Lehembre F, Seeler JS, Haupt Y and Dejean A: c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem. 275:13321–13329. 2000. View Article : Google Scholar : PubMed/NCBI
9	Liu G and Warbrick E: The p66 and p12 subunits of DNA polymerase delta are modified by ubiquitin and ubiquitin-like proteins. Biochem Biophys Res Commun. 349:360–366. 2006. View Article : Google Scholar : PubMed/NCBI
10	Tanaka K, Nishide J, Okazaki K, Kato H, Niwa O, Nakagawa T, Matsuda H, Kawamukai M and Murakami Y: Characterization of a fission yeast SUMO-1 homologue, pmt3p, required for multiple nuclear events, including the control of telomere length and chromosome segregation. Mol Cell Biol. 19:8660–8672. 1999.PubMed/NCBI
11	Bachant J, Alcasabas A, Blat Y, Kleckner N and Elledge SJ: The SUMO-1 isopeptidase Smt4 is linked to centromeric cohesion through SUMO-1 modification of DNA topoisomerase II. Mol Cell. 9:1169–1182. 2002. View Article : Google Scholar : PubMed/NCBI
12	Azuma Y, Arnaoutov A and Dasso M: SUMO-2/3 regulates topoisomerase II in mitosis. J Cell Biol. 163:477–487. 2003. View Article : Google Scholar : PubMed/NCBI
13	Wu N, Kong X, Ji Z, Zeng W, Potts PR, Yokomori K and Yu H: Scc1 sumoylation by Mms21 promotes sister chromatid recombination through counteracting Wapl. Genes Dev. 26:1473–1485. 2012. View Article : Google Scholar : PubMed/NCBI
14	McAleenan A, Cordon-Preciado V, Clemente-Blanco A, Liu IC, Sen N, Leonard J, Jarmuz A and Aragón L: SUMOylation of the α-kleisin subunit of cohesin is required for DNA damage-induced cohesion. Curr Biol. 22:1564–1575. 2012.
15	Luo K, Zhang H, Wang L, Yuan J and Lou Z: Sumoylation of MDC1 is important for proper DNA damage response. EMBO J. 31:3008–3019. 2012. View Article : Google Scholar : PubMed/NCBI
16	Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, et al: Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 44:239–245. 2010. View Article : Google Scholar : PubMed/NCBI
17	Correia AL and Bissell MJ: The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat. 15:39–49. 2012. View Article : Google Scholar : PubMed/NCBI
18	Doublier S, Belisario DC, Polimeni M, Annaratone L, Riganti C, Allia E, Ghigo D, Bosia A and Sapino A: HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer. 12:42012. View Article : Google Scholar
19	Brökers N, Le-Huu S, Vogel S, Hagos Y, Katschinski DM and Kleinschmidt M: Increased chemoresistance induced by inhibition of HIF-prolyl-hydroxylase domain enzymes. Cancer Sci. 101:129–136. 2010.PubMed/NCBI
20	Fabregat I, Roncero C and Fernández M: Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int. 27:155–162. 2007. View Article : Google Scholar : PubMed/NCBI
21	Homann N, Pauligk C, Luley K, et al: Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer. 130:1706–1713. 2012. View Article : Google Scholar
22	Kitagawa K, Kawada K, Morita S, et al: Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer. Ann Oncol. 23:743–747. 2012. View Article : Google Scholar
23	Nagai S, Davoodi N and Gasser SM: Nuclear organization in genome stability: SUMO connections. Cell Res. 21:474–485. 2011. View Article : Google Scholar : PubMed/NCBI
24	Cai Q and Robertson ES: Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization. PLoS One. 5:e126362010. View Article : Google Scholar : PubMed/NCBI
25	Ding B, Sun Y and Huang J: Overexpression of SKI oncoprotein leads to p53 degradation through regulation of MDM2 protein sumoylation. J Biol Chem. 287:14621–14630. 2012. View Article : Google Scholar : PubMed/NCBI
26	Bettermann K, Benesch M, Weis S and Haybaeck J: SUMOylation in carcinogenesis. Cancer Lett. 316:113–125. 2012. View Article : Google Scholar : PubMed/NCBI
27	Guo WH, Yuan LH, Xiao ZH, Liu D and Zhang JX: Overexpression of SUMO-1 in hepatocellular carcinoma: a latent target for diagnosis and therapy of hepatoma. J Cancer Res Clin Oncol. 137:533–541. 2011. View Article : Google Scholar : PubMed/NCBI
28	Kessler JD, Kahle KT, Sun T, et al: A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 335:348–353. 2012. View Article : Google Scholar : PubMed/NCBI
29	Wang Q, Xia N, Li T, et al: SUMO-specific protease 1 promotes prostate cancer progression and metastasis. Oncogene. 32:2493–2498. 2013. View Article : Google Scholar : PubMed/NCBI
30	Wartenberg M, Ling FC, Muschen M, et al: Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 17:503–505. 2003.